Show simple item record

dc.contributor.authorAndreyev, HJN
dc.contributor.authorMatthews, J
dc.contributor.authorAdams, C
dc.contributor.authorGothard, L
dc.contributor.authorLucy, C
dc.contributor.authorTovey, H
dc.contributor.authorBoyle, S
dc.contributor.authorAnbalagan, S
dc.contributor.authorMusallam, A
dc.contributor.authorYarnold, J
dc.contributor.authorAbraham, D
dc.contributor.authorBliss, J
dc.contributor.authorAbdi, BA
dc.contributor.authorTaylor, A
dc.contributor.authorHauer-Jensen, M
dc.coverage.spatialIreland
dc.date.accessioned2022-11-28T14:07:21Z
dc.date.available2022-11-28T14:07:21Z
dc.date.issued2022-03-01
dc.identifierS0167-8140(22)00029-9
dc.identifier.citationRadiotherapy and Oncology, 2022, 168 pp. 130 - 137en_US
dc.identifier.issn0167-8140
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5579
dc.identifier.eissn1879-0887
dc.identifier.eissn1879-0887
dc.identifier.doi10.1016/j.radonc.2022.01.024
dc.description.abstractBACKGROUND: Preclinical data suggest that combined gamma-tocotrienol with pentoxifylline ameliorates radiotherapy-induced gastrointestinal damage. AIM: To test whether gastrointestinal symptoms arising after radiotherapy, and persisting after maximal medical therapy, can be improved using Tocovid SupraBio 200 mg and pentoxifylline 400 mg orally twice daily for one year. Patients stratified by severity of symptoms, and randomised to active treatment or matched placebo were assessed after 12 months. The primary end point was improvement in gastrointestinal symptoms measured using the Inflammatory Bowel Disease Questionnaire, bowel subset score. Changes in bio-markers of fibrosis were assessed. RESULTS: 62 patients, median age 66, 34(55%) treated for prostate, 21(34%) gynaecological, 6(10%) anal and one(1%) rectal cancer were recruited; 40(65%) randomised to treatment, 22(35%) to placebo, 39 months (median) after radiotherapy completion. Gamma tocotrienol was not detected in serum in 41% of treated patients, despite good compliance with study medication. Treatment was completed in 28(70%) and 17(77%) patients in the treatment and placebo groups respectively. No improvement in symptom scores nor in quality of life was identified. Thirteen serious adverse events occurred. A transient ischaemic attack, was possibly related to pentoxifylline, others were assessed as unlikely to be related to treatment. Levels of EGF, PDGF and FGF were significantly reduced and consistent trends in reduced inflammation were seen during treatment but were not sustained once treatment ended. SUMMARY: This single centre study closed prematurely and therefore data interpretation is of necessity limited. No clinical benefit was demonstrated. However, biochemical data suggest that this intervention does have anti-inflammatory and anti-fibrotic effects.
dc.formatPrint-Electronic
dc.format.extent130 - 137
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIER IRELAND LTDen_US
dc.relation.ispartofRadiotherapy and Oncology
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectCancer
dc.subjectGamma tocopherol
dc.subjectGastrointestinal
dc.subjectPentoxifylline
dc.subjectRadiotherapy
dc.subjectToxicity
dc.subjectDouble-Blind Method
dc.subjectHumans
dc.subjectMale
dc.subjectPelvic Neoplasms
dc.subjectPentoxifylline
dc.subjectQuality of Life
dc.subjectTocotrienols
dc.subjectTreatment Outcome
dc.titleRandomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study.en_US
dc.typeJournal Article
dcterms.dateAccepted2022-01-16
dc.date.updated2022-11-24T14:53:09Z
rioxxterms.versionAMen_US
rioxxterms.versionofrecord10.1016/j.radonc.2022.01.024en_US
rioxxterms.licenseref.startdate2022-03-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35093409
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Breast Radiobiology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.radonc.2022.01.024
pubs.volume168
icr.researchteamTrans Breast Radiobiolen_US
icr.researchteamClin Trials & Stats Uniten_US
icr.researchteamClin Radiother Phy Suttonen_US
dc.contributor.icrauthorGothard, Lone
dc.contributor.icrauthorTovey, Holly
dc.contributor.icrauthorAnbalagan, Selvakumar
dc.contributor.icrauthorYarnold, John
dc.contributor.icrauthorBliss, Judith
icr.provenanceDeposited by Mrs Jessica Perry (impersonating Prof Judith Bliss) on 2022-11-24. Deposit type is initial. No. of files: 1. Files: Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline..pdf
icr.provenanceDeposited by Mrs Jessica Perry (impersonating Prof Judith Bliss) on 2022-11-28. Deposit type is subsequent. No. of files: 5. Files: Highlights of the PPALM study.pdf; TITLE PAGE.pdf; PPALM tables R1 .pdf; PPALM Figure 1 Consort diagram R1.pdf; PPALM - to the Green Journal R1 CLEAN.pdf


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record